Alvestrand A, Gutierrez A, Bucht H, Bergström J
Department of Renal Medicine, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.
Nephrol Dial Transplant. 1988;3(5):624-31. doi: 10.1093/oxfordjournals.ndt.a091717.
The effect of blood pressure reduction on the progression rate of chronic renal failure (CRF) was studied in 28 patients with CRF of diverse aetiology entering a prospective study (observation time 7-24 months, mean 16 months). Endogenous creatinine clearance was 12-66 ml/min (mean 30 +/- 3 ml/min). We aimed to keep the blood pressure below 160/90 mmHg. Dietary protein was not restricted. The progression rate of CRF was assessed from the regression coefficients of the regressions of creatinine clearance and the inverse of s-creatinine, respectively, on time. Progression rate and the means of all recordings of mean arterial blood pressure (MAP) and urinary protein excretion, respectively, in each patient during the prospective phase were compared with retrospective data from the proceeding period (observation time 4-25 months, mean 19 months). The patients received various combinations of antihypertensive drugs including diuretics, beta-blockers and vasodilatory drugs. In 19 patients MAP decreased from 109 +/- 2 to 102 +/- 2 mmHg (group I), whereas MAP increased from 105 +/- 2 to 108 +/- 2 mmHg in nine patients (group II). In group I proteinuria was significantly lower (P less than 0.05) and the progression of CRF was approximately 50% slower (P less than 0.01) in the prospective phase than in the retrospective phase; no changes were observed in group II. Calculated for all patients, significant correlations were observed between the change in MAP and the change in progression rate and protein excretion, respectively. These results indicate that lowering of blood pressure results in decreased proteinuria and retardation of the progression of CRF irrespective of the aetiology.
对28例病因各异的慢性肾衰竭(CRF)患者进行了前瞻性研究(观察时间7 - 24个月,平均16个月),以研究血压降低对慢性肾衰竭进展速度的影响。内生肌酐清除率为12 - 66 ml/分钟(平均30±3 ml/分钟)。我们的目标是将血压维持在160/90 mmHg以下。未限制饮食蛋白质摄入。分别根据肌酐清除率和血肌酐倒数对时间的回归系数评估CRF的进展速度。将前瞻性阶段每位患者平均动脉血压(MAP)和尿蛋白排泄的所有记录均值与前期(观察时间4 - 25个月,平均19个月)的回顾性数据进行比较。患者接受了包括利尿剂、β受体阻滞剂和血管扩张剂在内的各种降压药物组合。19例患者的MAP从109±2 mmHg降至102±2 mmHg(第一组),而9例患者的MAP从105±2 mmHg升至108±2 mmHg(第二组)。在第一组中,前瞻性阶段的蛋白尿显著降低(P<0.05),CRF的进展比回顾性阶段慢约50%(P<0.01);第二组未观察到变化。对所有患者计算得出,MAP变化与进展速度变化和蛋白排泄变化之间分别存在显著相关性。这些结果表明,无论病因如何,降低血压都会导致蛋白尿减少和CRF进展减缓。